

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
01 July 2021 (01.07.2021)

(10) International Publication Number
WO 2021/133896 A8

(51) International Patent Classification:

A61K 31/18 (2006.01) A61P 29/00 (2006.01)
C07C 311/37 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/066811

(22) International Filing Date:

23 December 2020 (23.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/953,381 24 December 2019 (24.12.2019) US

(71) Applicant: **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, MA 02215 (US).

(72) Inventors: **GRAY, Nathanael, S.**; 26 Greenview Avenue, Boston, MA 02130 (US). **ZHANG, Tinghu**; 91 Chestnut Street, #3, Brookline, MA 02445 (US). **CHE, Jianwei**; 183 Morse St., Sharon, MA 02067 (US). **KWIATKOWSKI, Nicholas, Paul**; 137 Beaconsfield Road #6, Brookline, MA 02445 (US). **FAN, Mengyang**; 5 Barrows Street, Apt. 2A, Allston, MA 02134 (US). **LU, Wenchao**; 38 Juniper Street, Apt. 103, Brookline, MA 02445 (US).

(74) Agent: **CHAO, Jessica, J.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

(54) Title: TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF

NCI-H226 cells, 5 Days





FIG. 17



(57) Abstract: Provided herein are compounds of (I-A), (I-B), or (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are methods, uses, and kits involving the inventive compounds and pharmaceutical compositions thereof for treating and/or preventing diseases (*e.g.*, proliferative diseases (*e.g.*, cancers), inflammatory diseases (*e.g.*, fibrosis), autoimmune diseases (*e.g.*, sclerosis)) in a subject. Provided are methods of inhibiting the activity of a transcription factor (*e.g.*, TEAD, such as TEAD1, TEAD2, TEAD3, TEAD4) and/or inhibiting the transcription of a gene (*e.g.*, a gene controlled or regulated by a transcription factor (*e.g.*, TEAD)) in a subject.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

09 June 2022 (09.06.2022)

(15) Information about Correction:

see Notice of 09 June 2022 (09.06.2022)